Today: 21 July 2026
Browse Category

Pharmaceuticals 22 October 2025 - 2 November 2025

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor and Viagra, to its 2020 partnership with BioNTech delivering the first approved COVID-19 vaccine, Pfizer’s innovations have had global impact. Today the company employs about 81,000 people worldwide and operates 35+ manufacturing sitesxtalks.com. It was the world’s top drugmaker by sales during the pandemic boom, and even with post-COVID declines Pfizer is expected to generate ~$62 billion in revenue in 2025 – underscoring its massive scalets2.tech.
2 November 2025
·
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

As of Oct. 31 close, Eli Lilly was around $862–864 Stockanalysis Marketbeat. That’s up ~9–10% from early October Nasdaq. Trading volumes have been heavy, and LLY remains near its 52-week high Marketbeat. MarketBeat notes LLY’s 50-day moving average is ~$780 Marketbeat, reflecting the recent surge. Institutional ownership is high and sentiment is bullish.
2 November 2025
·
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai and a simultaneous $60M financing sent the stock soaring. Intraday Oct 17 it jumped from $0.47 to $2.39ts2.tech. By Oct 31 the stock closed at $2.20, a 51.7% gain on that day alonets2.tech. This means RANI is up roughly +20% in the past week and about +330% in Octoberinvesting.cominvesting.com.This rally propelled RANI well above Nasdaq’s $1 minimum bidts2.tech. Volatility and volume have been extreme: in mid‑October daily volume hit 100–200 million sharests2.tech. All told, RANI’s late‑Oct performance turned it from a near-penny stock into a mid-cap biotech in two weeks.
1 November 2025
·
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on recordts2.techreportify.cn. This vastly outperforms both the S&P 500 and the broader pharma industrytimesunion.comreportify.cn – a testament to investors’ optimism in AbbVie’s post-Humira strategy. The stock’s 52-week range spans from a low of about $163.8 to the recent peak around $244.8 on October 1stts2.tech.
31 October 2025
··
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

On Oct. 30, 2025 Moderna’s stock jumped sharply. Midday trading saw MRNA up ~11.7% to about $27.56tradingview.com, reversing much of September–October’s slide. This followed a STAT News report that Moderna has held buyout or partnership talks with at least one large drugmakertradingview.com. Moderna’s shares had been languishing near all-time lowstradingview.com, so today’s news sparked a relief rally. Even so, with the recent gain the stock remains roughly 37% below its Jan. 2025 pricetradingview.com. Moderna declined to comment on the rumors. A company spokesperson reiterated that Moderna is “confident in our strategy,” highlighting that it has advanced several new products this yeartradingview.com.
30 October 2025
··
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlierts2.tech – as investors grappled with the end of Covid vaccine and treatment revenues. That all changed in early October. In the final trading week of September, Pfizer shares jumped ~15%, rallying from roughly $23.6 to about $27.2 by Oct. 1ts2.tech. This dramatic move was largely driven by two key announcements and marked one of PFE’s strongest weekly gains in years.
30 October 2025
··
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly’s stock has moved sharply in recent weeks. After languishing around the mid-$700s in late September, the stock soared in early October. Between Sept. 29 and Oct. 1 it jumped over 9%, briefly touching the low $830s ts2.tech. Analysts noted this jump was fueled by a “perfect storm” of good news: better-than-expected trial results and anticipation of strong earnings. Trading volume was heavy, and by Oct. 23 shares were holding near $818 ts2.tech, about 6% higher on the year.
30 October 2025
·
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener, the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts.
30 October 2025
····
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck’s stock price dipped on Oct 30, 2025 even as it delivered a strong third-quarter report. The company posted $17.28 B in Q3 sales and $2.58 adjusted EPS – above analyst forecastsmarketscreener.com. Sales of Keytruda, its blockbuster cancer drug, grew about 10%marketscreener.com, offsetting a drop in Gardasil vaccine revenue. Despite the beat, Merck narrowed its 2025 sales outlook while slightly raising profit guidancemarketscreener.com, a cautious stance that likely weighed on the share price.
30 October 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly’s stock has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly. Trading volume and technical indicators suggest a consolidation phase after the recent rallyintellectia.aiintellectia.ai.
30 October 2025
···
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics Inc. – a small Cambridge, MA biotech formerly known as Eterna Therapeutics – saw its stock skyrocket on October 29 after unveiling a major collaboration to advance its cutting-edge cancer therapy. By Wednesday afternoon, ERNA shares were up about 48% as investors piled in on news that Ernexa is partnering with Cellipont Bioservices to scale up ERNA-101 for clinical trialsstocktwits.com. “Shares of Ernexa Therapeutics traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company,” Stocktwits reportedstocktwits.com. The stock, which had closed around $1.20 the prior day, surged to roughly $1.80 intraday, marking one of its biggest single-day gains this year.
29 October 2025
··
Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Key points: Regeneron shares recently traded around $580–$585 after a slight pullback earlier in the month investing.com. Over the past week REGN is up roughly 1–2%, recovering from a low in the high $570s investing.com. In its Oct. 28 earnings release, Regeneron reported Q3 2025 revenue of $3.75 billion, led by a 27% jump in Dupixent to $4.86 billion stocktitan.net. The company also won FDA approval for Libtayo in a high-risk skin cancer indication, and positive EU reviews for Libtayo and Dupixent stocktitan.net. Wall Street analysts have largely “buy” ratings on REGN: the consensus price target is about $725, implying ~25–27% upside tikr.com. The broader biotech sector has been rallying – for example, biotech ETFs are 25–34% higher since spring genengnews.com, outpacing the 24% gain in the S&P 500 over that span genengnews.com. Regeneron is still down from its 2024 highs, but recent drug wins and solid earnings are fueling renewed investor optimism.
28 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coveragecontractpharma.comgxpnews.net; GxP Newsgxpnews.netgxpnews.net; The Medicine Maker/Conexiantconexiant.comconexiant.com; GlobeNewswireglobenewswire.com; Evaluate Pharma forecastevaluate.comevaluate.com; Reutersreuters.com; TechStock² / TS2 Techts2.techts2.tech; TS2 Techts2.techts2.tech.
28 October 2025
····
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18% from a year priorts2.tech. It languished near the bottom of its 52-week rangets2.tech as the company faced a post-pandemic hangover: revenues from its COVID-19 vaccine and pill plummeted from $37.8B in 2022 to about $12.5B in 2024ts2.tech. Wall Street projected Pfizer’s EPS would fall by more than half from 2022 to 2025ts2.tech, reflecting this “COVID cliff” in sales and ongoing patent cliffs ahead. These factors, along with drug pricing worries, weighed heavily on investor sentiment through Q3 2025.
27 October 2025
··
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is closing, its novel treatments may reach patients faster under Novartis’s umbrella. Investors now await the finalization of the deal, as Wall Street cheers another biotech success story in the making. 🏥💥
26 October 2025
····
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run. The stock has surged ~28% on Oct 23 after a prior drop. Recent catalysts include completion of a 1-year Phase 3 trial showing robust, sustained efficacy revivapharma.com, and plans for an FDA meeting in Q4 2025 toward a 2026 NDA revivapharma.com. Reviva also raised capital via equity offerings to fund its CNS pipeline. Analysts remain extremely bullish – consensus is “Strong Buy” with an average 12‑month target around $6.25 investing.com investing.com. By comparison, MarketBeat reports a mean $4.86 target marketbeat.com. In the broader biotech space, industry news and deals are driving rallies.
24 October 2025
···
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on recorddirectorstalkinterviews.com. By comparison, the S&P 500 healthcare index is up only around half that, so AbbVie is outperforming its sector. The stock’s 52-week high was about $244.8ts2.tech, and its low in the past year was ~$163.8. Notably, AbbVie surged to a record high in mid-September after the company announced a patent settlement ensuring no U.S. generics for its key drug Rinvoq until 2037reuters.com. That news – effectively a four-year extension of exclusivity – drove a 4% one-day jump in ABBV stockreuters.com. Analysts cheered the development; J.P. Morgan’s Chris Schott said the deal gives AbbVie “several more years of runway on one of its key growth drivers,” buying time to develop other drugs ahead of major mid-2030s patent lossesreuters.com. William Blair’s Matt Phipps added it could add ~$2 billion to Rinvoq’s peak sales by protecting the franchise longerreuters.com. This optimism around AbbVie’s future revenue stream helped fuel the stock’s late-summer rally.
23 October 2025
·
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Eli Lilly has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on Oct. 1ts2.techts2.tech. Trading volume was heavy and analysts pointed to a “perfect storm” of news – Eli Lilly’s weight-loss and Alzheimer’s drug advances were cited as key drivers. As one tech-stock analysis observed, traders noted “bullish options activity and growing excitement over Lilly’s weight-loss drugs and Alzheimer’s research” fueling the rallyts2.tech. By Oct. 23, LLY was trading near $818tradingview.com, solidly above its pre-September levels. Overall, the stock is up roughly 6% year-to-date, about matching the S&P 500 health-care indextradingview.com.
23 October 2025
··
Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the company announced Arbli™ was available through major wholesalers – making it the first FDA-approved liquid losartan on the market ts2.tech. That morning, SCNX shares surged over 30% from the prior day’s $0.72 close, even hitting an intraday high around $1.12 before profit-taking set in ts2.tech. By mid-day Oct. 16, Reuters reported the stock had pulled back near $0.71 ts2.tech, indicating traders sold into the early pop. Still, the news established a new baseline of investor optimism.
23 October 2025
··
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right tied to an FDA approval for idiopathic hypersomnia, valuing the deal at up to $2.1 billion prnewswire.com. The all-cash offer represents roughly a 12% premium to Avadel’s recent trading range. Avadel CEO Greg Divis hailed the terms as “a compelling outcome for our shareholders” prnewswire.com, while Alkermes CEO Richard Pops said the deal is “a pivotal step” to accelerate Alkermes’ entry into the sleep-medicine market prnewswire.com. Avadel’s board and Alkermes’ board have approved the merger, which is expected to close in Q1 2026 pending regulatory and shareholder approval.
22 October 2025
·····
1 … 39 40 41 42 43 44
Go toTop